生物技术公司莫德纳(MRNA)今日盘中股价大跌6.19%,引发市场高度关注。从最新消息看,导致该股下挫的主要原因是该公司旗下两款处于临床试验阶段的RSV疫苗因为潜在安全隐患而被监管部门叫停试验。
据了解,莫德纳的两款呼吸道合胞病毒(RSV)疫苗mRNA-1345和mRNA-1365的临床试验近期被美国食品药品监督管理局(FDA)叫停。原因是临床试验中有多名接种这两款疫苗的婴幼儿在感染RSV后出现了严重的下呼吸道感染。
莫德纳一直将RSV疫苗视为公司在新冠疫苗之外另一个重要赛道,寄予厚望能在该领域取得突破。但FDA此番举措无疑给公司在RSV疫苗领域的发展蒙上了阴影,引发市场对莫德纳长期增长前景的担忧,从而推动股价大幅下挫。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.